Sartorius AG Reports First Quarter Results for 2024

Sartorius AG, a leading life sciences group, announced its first quarter results for 2024, aligning with expectations despite a challenging market. The company registered a near 10 percent increase in order intake in constant currencies, although sales revenue saw a 7.6 percent drop. The EBITDA margin remained robust at 28.6 percent.

Significant growth was observed in the Americas with a 26.1 percent increase in order intake, while China and Europe exhibited weak demand, impacting the equipment business. CEO Joachim Kreuzburg highlighted the resilience in core consumables business and advancements in cell and gene therapies, though noting greater volatility and investment reluctance in certain regions.

For 2024, Sartorius projects a sales revenue growth in the mid to high single-digit percentage range, with an expected EBITDA margin just over 30 percent. The company maintains a cautious outlook, mindful of potential geopolitical and economic challenges.